Tesofensine vs. cagrilintide: what the data actually shows

What's this video probably claiming?

Based on the caption and category context, @coachcam.peps3 is likely walking viewers through a side-by-side comparison of tesofensine and cagrilintide (commonly called "Cagri"), framing them as emerging alternatives or additions to the GLP-1 weight loss drug space. That's a reasonable topic to cover. Tesofensine is a triple monoamine reuptake inhibitor that was originally developed for Parkinson's disease before researchers noticed significant weight loss as a side effect. Cagrilintide is an amylin analogue being developed by Novo Nordisk, currently being studied in combination with semaglutide as "CagriSema." The creator is probably positioning these as next-generation options, comparing mechanisms, weight loss percentages, and possibly hinting at their availability through channels like peptide suppliers. The comparison framing is where things can get slippery fast, because these two compounds operate through completely different biological pathways and have very different safety and regulatory profiles.

What does the science actually show?

Tesofensine's most cited human data comes from a 2008 trial by Astrup et al. published in The Lancet, in which participants on 0.5 mg daily lost roughly 10.6% body weight over 24 weeks compared to 2.2% on placebo. That sounds impressive until you factor in the side effect profile: elevated heart rate, dry mouth, insomnia, and blood pressure changes that spooked regulators enough that the drug never reached market approval in the U.S. or EU. Cagrilintide has a cleaner recent track record. A 2023 phase 2 trial published in The Lancet by Enebo et al. showed that 4.5 mg cagrilintide weekly produced around 10.8% weight loss over 26 weeks as monotherapy. The real headline number comes from CagriSema combination data, where Novo Nordisk's phase 3 REDEFINE trials are targeting reductions potentially exceeding 20%, though full results are still pending as of mid-2024. These are not the same class of drug, and conflating their risk-benefit profiles is where most social media content goes wrong.

Where does the social media noise diverge from clinical reality?

The biggest distortion that tends to follow this kind of comparison content is the implication that tesofensine is a reasonable "alternative" to GLP-1 drugs or amylin analogues for people who can't access semaglutide or tirzepatide. It isn't. Tesofensine acts on dopamine, serotonin, and norepinephrine reuptake, which means its cardiovascular and neurological risk profile is meaningfully different from peptide-based weight loss agents. There's no long-term cardiovascular outcome data for tesofensine comparable to SUSTAIN or LEADER trials that support semaglutide and liraglutide use. Cagrilintide, meanwhile, is not currently approved anywhere as a standalone drug, and CagriSema is not yet approved either. Creators who frame these compounds as ready-to-use options are skipping over the fact that neither has cleared the regulatory bar for clinical use in weight management. Social media timelines on drug availability are almost always compressed beyond what the actual trial pipelines support.

What should you actually know?

If you're genuinely interested in where weight loss pharmacology is heading, tesofensine and cagrilintide are legitimately interesting science. But they are not interchangeable, and they are not at the same stage of development or approval. Tesofensine has been in clinical limbo for over a decade due to safety concerns that regulators have not been willing to dismiss. Cagrilintide, particularly in combination with semaglutide, represents one of the more credible next-generation approaches in the pipeline, but "promising phase 2 and early phase 3 data" is not the same as an approved treatment you should be sourcing outside of a clinical trial. Anyone comparing these two compounds on a 60-second video without discussing cardiovascular signals, regulatory status, and the complete absence of long-term safety data for tesofensine is giving you an incomplete picture. A regulated telehealth provider can walk you through what's actually available and appropriate for your situation.